CNBC's Meg Tirrell reports on the latest developments on a federal court invalidating Allergan's eye drug patents.
CNBC's Meg Tirrell reports on Allergan sinking after a federal judge invalidates patents on their drug Restasis.
CNBC's Meg Tirrell reports on President Trump's comments on health insurers during a Cabinet meeting sending insurance stocks down.
CNBC's Meg Tirrell reports on Spark Therapeutics shares jumping after the FDA panel votes in favor of the company's gene therapy.
CNBC's Meg Tirrell reports on Baxter International's report of minimal damage at its Puerto Rican sites and how it's working with the FDA to support U.S. product supply.
But the company said it expects the impact to be mitigated by positive performance in other areas of the business.
CNBC's Meg Tirrell reports that Spark Therapeutics has received a 16-0 vote from an FDA panel in favor of a new genetic treatment to treat a rare, inherited form of blindness
Meg Green, Founder, Meg Green & Associates; Steve Grasso, Stuart Frankel; and CNBC's Rick Santelli discuss the day's market activity and what investors should consider.
CNBC's Meg Tirrell reports Sparks Therapeutics could be the first biotech company in the U.S. to get approval from the FDA to treat a rare form of blindness at its genetic root.
The group is the latest to call on lawmakers to examine Allergan's controversial patent deal with a Native American tribe.